Influenza Vaccines in the United States by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus Type A and Influenza Virus Type B), and by Age Group (Pediatrics and Adults) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2030

The U.S. Influenza Vaccines Market was valued at US$ 2.7 billion in 2019 and is expected to witness a CAGR of 16.3% over the forecast period (2019–2027).

United States Influenza Vaccines Market Overview

The report study researched by Research Industry US gives comprehensive knowledge and valuable insights about the United States Influenza Vaccines Market. Also, the study attempts to deliver significant and detailed insights into the current market prospect and emerging growth scenarios. The report on the United States Influenza Vaccines Market also emphasizes on market players as well as the new entrants in the market landscape. The U.S. influenza vaccines market was valued at US$ 2.7 billion in 2019 and is expected to witness a CAGR of 16.3% over the forecast period (2019–2027). The United States Influenza Vaccines Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide U.S Influenza Vaccines Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the U.S Influenza Vaccines industry. Impact of Coronavirus (COVID-19) on United States Influenza Vaccines Market. Coronavirus (COVID-19) is spreading across the world with a serious impact on the economy and the global market. The report considers and accounts for the impact of COVID-19 on United States Influenza Vaccines Market across all the segments, regions, countries, and key players. North America and Europe are worst-hit countries by Coronavirus which are key players in the global economy. The report provides a detailed analysis of the impact on the market, growth strategies, supply china disruption, consumption pattern of the United States Influenza Vaccines Market.

Market Segmentation

The report provides market size with 2019 as the base year in consideration and a yearly forecast until 2030 in terms of Revenue (USD Million). The estimates for all segments including type and application have been provided on a regional basis for the forecast period mentioned above. We have implemented a mix of top-down and bottom-up approaches for market sizing, analyzing the key regional markets, dynamics, and trends for various applications. Major and Promising Vaccine covered in the report are as follows: 1. Fluzone High–Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN–100 11. M–001 12. VAX–2012Q 13. TAK – 850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Competitive Landscape: Key players profile in the report include Sanofi Pasteur Seqirus Vaccines Ltd. GlaxoSmithKline Plc. Medimmune VaxInnate Mitsubishi Tanabe Pharma BiondVax Pharmaceuticals Ltd Seqirus AstraZenecca Protein Sciences Corporation Novavax Daiichi–Sankyo The report of United States Influenza Vaccines Market studies the key players present in the market. The chapter includes the competitive landscape section which provides the full and in-depth analysis of the current market trends, changing technologies, and developments that will be beneficial for the companies, which are competing in the market. The report offers an overview of revenue, demand, and supply of data, futuristic cost, and growth analysis during the projected year. In addition to a brief overview of the company, analysts shed light on their valuation and evolution. It also discusses the list of important products and the ones in the pipeline. The competitive landscape is analyzed by understanding the approaches of the companies and the initiatives they have taken in recent years to triumph over the intensive competition. Frequently Asked Questions (FAQ):
  • What is the size of the United States Influenza Vaccines Market?
  • How much will this market be worth from 2020 to 2030?
  • What are the major deals happenings in the United States Influenza Vaccines Market?
  • Which country is expected to hold the highest market share in the United States Influenza Vaccines Market?
  • What are production processes, major issues, and solutions to mitigate the development risk?
  • Who are the top players and what are their activities, revenue, recent developments, and prospects?
  • What are the main drivers and restraints in the United States Influenza Vaccines Market?
  • Which are the largest revenue generating products, services or regions and their comparative growth rate?

1. Executive Summary

2. United States Influenza Vaccines Market Size & Analysis (2013 - 2030)

3. United States Number of Persons Vaccinated with Influenza Vaccines (2013 - 2030)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines

4. Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Inhibitors

5. United States Influenza Vaccines Pricing Trends & Analysis

6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)

7. United States Influenza Vaccines Distribution & Demand (2010 - 2018)

8. Effectiveness of Influenza Vaccines in United States (2004 – 2018)

9. Rapid Diagnostic Testing for the Management of Influenza

10. Distribution Channel & Technique of Influenza Vaccination in United States

11. United States Influenza Vaccines Reimbursement Policies & Regulatory System
11.1 Reimbursement Policies
11.2 Regulation System

12. Major Deals in United States Influenza Vaccines Market
12.1 Merger & Acquisitions
12.2 Collaboration Deal
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Distribution Agreement

13. Promising Influenza Vaccines in Clinical Development

14. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
14.1 Year 2018
14.2 Year 2017

15. Key Companies Analysis
15.1 Sanofi Pasteur
15.1.1 Business Overview
15.1.2 Influenza Vaccines Portfolio
15.1.3 Influenza Vaccine Value Sales Analysis
15.1.4 Recent Development
15.2 GlaxoSmithKline (GSK)
15.2.1 Business Overview
15.2.2 Influenza Vaccines Portfolio
15.2.3 Influenza Vaccine Sales Value Analysis
15.2.4 Recent Development
15.3 Seqirus
15.3.1 Business Overview
15.3.2 Influenza Vaccines Portfolios
15.3.3 Recent Development
15.4 AstraZeneca
15.4.1 Business Overview
15.4.2 Influenza Vaccines Portfolio
15.4.3 Influenza Vaccine Sales Value Analysis
15.4.4 Recent Development

Key players profile in the report include Sanofi Pasteur Seqirus Vaccines Ltd. GlaxoSmithKline Plc. Medimmune VaxInnate Mitsubishi Tanabe Pharma BiondVax Pharmaceuticals Ltd Seqirus AstraZenecca Protein Sciences Corporation Novavax Daiichi–Sankyo

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS